Compare Novavax Inc (NVAX) vs Oatly Group AB - ADR (OTLY) Price & Performance

Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.

The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.

OTLY trades at $10.59, up 2.12% today, with a bearish technical signal but improving fundamentals. Revenue grew to $862.46M in 2025, and net losses narrowed to -$152.77M, reflecting margin improvements. The company raised its 2026 revenue outlook after Q2 results, driving positive sentiment. However, negative cash flows and high debt-to-asset ratio of 66.53% in 2025 pose risks. Analyst consensus is mixed with a $12.28 price target, indicating modest upside potential from current levels.

Outlook: OTLY shows operational progress with revenue growth and reduced losses, but profitability remains elusive. Investment opportunity hinges on sustained margin expansion and positive EBITDA. Key risks include cash burn, competitive pressures, and leverage. Investors should weigh turnaround potential against financial stability concerns.